Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" ...

Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst stock ...

Catalyst Pharmaceuticals (CPRX) announced that the company and its licensor SERB S.A. have entered into a Settlement Agreement with Teva ...

Catalyst Pharmaceuticals and its licensor SERB entered into a settlement agreement with Teva Pharmaceuticals resolving patent litigation brought by Catalyst and SERB in response to Teva's plans for a ...

Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...

Catalyst Pharmaceuticals' controversial $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...